Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver Diseases.
Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver Diseases.
复制标题
DOI：
10.3390/diseases5010011
复制
发表时间：
2017-03-08
期刊：
影响因子：
--
通讯作者：
Zhong XB
中科院分区：
文献类型：
--
作者：
Pope C;Mishra S;Russell J;Zhou Q;Zhong XB
H19是一种长链非编码RNA，由基因组印迹通过H19和IGF2之间位点的甲基化调控。H19在正常肝脏发育、控制增殖和影响参与控制胎儿发育的重要网络的基因中发挥重要作用。H19在疾病进展中也起重要作用，特别是在肝细胞癌中。H19参与了许多影响疾病过程的表观遗传调控，如通过组蛋白乙酰化激活miR-200通路，抑制上皮-间质转化，抑制肿瘤转移。此外，H19的正常调控在诸如肝细胞癌等疾病中受到干扰。在这种疾病中，异常的表观遗传维持导致IGF2双等位基因表达，导致不受控制的细胞增殖。本文旨在从H19的表观遗传调控以及H19如何通过表观遗传机制调控正常肝功能和疾病等方面，进一步研究利用H19进行药物开发和肝脏疾病治疗。
H19 is a long non-coding RNA regulated by genomic imprinting through methylation at the locus between H19 and IGF2. H19 is important in normal liver development, controlling proliferation and impacting genes involved in an important network controlling fetal development. H19 also plays a major role in disease progression, particularly in hepatocellular carcinoma. H19 participates in the epigenetic regulation of many processes impacting diseases, such as activating the miR-200 pathway by histone acetylation to inhibit the epithelial-mesenchymal transition to suppress tumor metastasis. Furthermore, H19’s normal regulation is disturbed in diseases, such as hepatocellular carcinoma. In this disease, aberrant epigenetic maintenance results in biallelic expression of IGF2, leading to uncontrolled cellular proliferation. This review aims to further research utilizing H19 for drug discovery and the treatment of liver diseases by focusing on both the epigenetic regulation of H19 and how H19 regulates normal liver functions and diseases, particularly by epigenetic mechanisms.